Sekar Kathiresan, Chief Executive Officer at Verve Therapeutics, Inc. (VERV), sold 96,616 shares at $40.02 ($3.9M) on 2021-12-27, disclosed to the SEC on 2021-12-29.
Open-market sale of $3.9M VERV by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $40.02 | 36,443 | $1.5M | 37.6% |
| 2 | $40.02 | 36,443 | $1.5M | 37.6% |
| 3 | $41.24 | 4,787 | $197K | 5.1% |
| 4 | $41.24 | 4,787 | $197K | 5.1% |
| 5 | $42.21 | 770 | $33K | 0.8% |
| 6 | $39.90 | 6,693 |
| $267K |
| 6.9% |
| 7 | $39.90 | 6,693 | $267K | 6.9% |
| Total | $40.14 avg | 96,616 | $3.9M | 100% |
| Filing → |
| VERV | SELL | 2022-08-11 | $1.5M | — | Filing → |
| VERV | SELL | 2022-07-21 | $1.5M | — | Filing → |
| VERV | SELL | 2022-01-06 | $75K | — | Filing → |